The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Concise Review: Induced Pluripotent Stem Cell‐Derived Mesenchymal Stem Cells: Progress Toward Safe Clinical Products
Open accessAbstract
Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with "safe harbor" vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Generation of germline-competent induced pluripotent stem cells
Okita, K., Ichisaka, T., & Yamanaka, S. (2007) · Nature · doi:10.1038/nature05934 · Cited by 4,299
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., & Yamanaka, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1374 · Cited by 2,380
Epigenetic memory in induced pluripotent stem cells
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M. J., Ji, H., Ehrlich, L. I. R., et al. (2010) · Nature · doi:10.1038/nature09342 · Cited by 2,313
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Horwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., Koo, W. W. K., Gordon, P. L., Neel, M., Sussman, M., Orchard, P., Marx, J. C., Pyeritz, R. E., et al. (1999) · Nature Medicine · doi:10.1038/6529 · Cited by 1,824
Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells
Lister, R., Pelizzola, M., Kida, Y. S., Hawkins, R. D., Nery, J. R., Hon, G., Antosiewicz-Bourget, J., O’Malley, R., Castanon, R., Klugman, S., et al. (2011) · Nature · doi:10.1038/nature09798 · Cited by 1,549
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., & Keiliss-Borok, I. V. (1974) · Transplantation · doi:10.1097/00007890-197404000-00001 · Cited by 1,431
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Somatic coding mutations in human induced pluripotent stem cells
Gore, A., Li, Z., Fung, H.-L., Young, J. E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M. A., Kiskinis, E., et al. (2011) · Nature · doi:10.1038/nature09805 · Cited by 1,273
Wernig, M., Zhao, J.-P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., Constantine-Paton, M., Isacson, O., & Jaenisch, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801677105 · Cited by 1,216
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Copy number variation and selection during reprogramming to pluripotency
Hussein, S. M., Batada, N. N., Vuoristo, S., Ching, R. W., Autio, R., Närvä, E., Ng, S., Sourour, M., Hämäläinen, R., Olsson, C., et al. (2011) · Nature · doi:10.1038/nature09871 · Cited by 954
Amariglio, N., Hirshberg, A., Scheithauer, B. W., Cohen, Y., Loewenthal, R., Trakhtenbrot, L., Paz, N., Koren-Michowitz, M., Waldman, D., Leider-Trejo, L., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000029 · Cited by 933
Human embryonic stem cells express an immunogenic nonhuman sialic acid
Martin, M. J., Muotri, A., Gage, F., & Varki, A. (2005) · Nature Medicine · doi:10.1038/nm1181 · Cited by 932
Laurent, L. C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., Lynch, C., Harness, J. V., Lee, S., Barrero, M. J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2010.12.003 · Cited by 890
Mesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759
Identification and classification of chromosomal aberrations in human induced pluripotent stem cells
Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J.-C., Yakir, B., Clark, A. T., Plath, K., Lowry, W. E., & Benvenisty, N. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.07.017 · Cited by 756
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues
Hanna, J. H., Saha, K., & Jaenisch, R. (2010) · Cell · doi:10.1016/j.cell.2010.10.008 · Cited by 698
Rosová, I., Dao, M., Capoccia, B., Link, D., & Nolta, J. A. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1104 · Cited by 692
Self-citationSackstein, R., Merzaban, J. S., Cain, D. W., Dagia, N. M., Spencer, J. A., Lin, C. P., & Wohlgemuth, R. (2008) · Nature Medicine · doi:10.1038/nm1703 · Cited by 641
Lian, Q., Zhang, Y., Zhang, J., Zhang, H. K., Wu, X., Zhang, Y., Lam, F. F.-Y., Kang, S., Xia, J. C., Lai, W.-H., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898312 · Cited by 618
Mesenchymal stem cell therapy: Two steps forward, one step back
Ankrum, J., & Karp, J. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.02.005 · Cited by 614
Reprogramming of Human Primary Somatic Cells by OCT4 and Chemical Compounds
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K., & Ding, S. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.015 · Cited by 597
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., Böhm, M., Nowrouzi, A., Ball, C. R., Glimm, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003548 · Cited by 532
Methods for making induced pluripotent stem cells: reprogramming à la carte
González, F., Boué, S., & Belmonte, J. C. I. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2937 · Cited by 508
Mesenchymal stem cells for the treatment of neurodegenerative disease
Joyce, N., Annett, G., Wirthlin, L., Olson, S., Bauer, G., & Nolta, J. A. (2010) · Regenerative Medicine · doi:10.2217/rme.10.72 · Cited by 501
Self-citationFDA Regulation of Stem-Cell–Based Therapies
Halme, D. G., & Kessler, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmhpr063086 · Cited by 405
Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells
Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010) · Stem Cells · doi:10.1002/stem.459 · Cited by 376
Prasad, V. K., Lucas, K. G., Kleiner, G. I., Talano, J. A. M., Jacobsohn, D., Broadwater, G., Monroy, R., & Kurtzberg, J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.014 · Cited by 317
Turning straw into gold: directing cell fate for regenerative medicine
Cohen, D. E., & Melton, D. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2938 · Cited by 287
Self-renewal and differentiation capacity of young and aged stem cells
Roobrouck, V. D., Ulloa-Montoya, F., & Verfaillie, C. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.006 · Cited by 268
MSCs: Biological characteristics, clinical applications and their outstanding concerns
Si, Y.-L., Zhao, Y.-L., Hao, H.-J., Fu, X.-B., & Han, W.-D. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.005 · Cited by 259
Optimizing mesenchymal stem cell-based therapeutics
Wagner, J., Kean, T., Young, R., Dennis, J. E., & Caplan, A. I. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.08.009 · Cited by 180
Cardiac cell therapy: Lessons from clinical trials
Menasche, P. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.06.010 · Cited by 172
Katsara, O., Mahaira, L. G., Iliopoulou, E. G., Moustaki, A., Antsaklis, A., Loutradis, D., Stefanidis, K., Baxevanis, C. N., Papamichail, M., & Perez, S. A. (2011) · Stem Cells and Development · doi:10.1089/scd.2010.0280 · Cited by 170
Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors
Meyerrose, T., Olson, S., Pontow, S., Kalomoiris, S., Jung, Y., Annett, G., Bauer, G., & Nolta, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.013 · Cited by 169
Self-citationCapoccia, B. J., Robson, D. L., Levac, K. D., Maxwell, D. J., Hohm, S. A., Neelamkavil, M. J., Bell, G. I., Xenocostas, A., Link, D. C., Piwnica-Worms, D., et al. (2009) · Blood · doi:10.1182/blood-2008-04-154567 · Cited by 166
Self-citationHomografts of Bone Marrow in Dogs After Lethal Total-Body Radiation
Thomas, E. D., Ashley, C. A., LOCHTE, H. L., Jaretzki, A., Sahler, O. D., & Ferrebee, J. W. (1959) · Blood · doi:10.1182/blood.v14.6.720.720 · Cited by 152
Fierro, F. A., Kalomoiris, S., Søndergaard, C. S., & Nolta, J. A. (2011) · Stem Cells · doi:10.1002/stem.720 · Cited by 135
Self-citationMesenchymal Stem Cells as Vehicles for Gene Delivery
Mosca, J. D., Hendricks, J. K., Buyaner, D., Davis-Sproul, J. M., Chuang, L.-C., Majumdar, M. K., Chopra, R., Barry, F., Murphy, M. J., Thiede, M. A., et al. (2000) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200010001-00011 · Cited by 125
Meyerrose, T. E., Roberts, M. S., Ohlemiller, K. K., Vogler, C. A., Wirthlin, L., Nolta, J. A., & Sands, M. S. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0008 · Cited by 94
Self-citationGruenloh, W., Kambal, A., Søndergaard, C. S., McGee, J., Nacey, C., Kalomoiris, S., Pepper, K. A., Olson, S. D., Fierro, F. A., & Nolta, J. A. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0460 · Cited by 91
Self-citationIn vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
Bauer, G., Dao, M., Case, S. S., Meyerrose, T., Wirthlin, L., Zhou, P., Wang, X.-L., Herrbrich, P. E., Arevalo, J., Csik, S., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.93 · Cited by 77
Self-citationKambal, A., Mitchell, G., Cary, W., Gruenloh, W., Jung, Y., Kalomoiris, S., Nacey, C., McGee, J., Lindsey, M., Fury, B., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.269 · Cited by 76
Self-citationGeron trial resumes, but standards for stem cell trials remain elusive
Strauss, S. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-989 · Cited by 75
Bone marrow stromal cells as a vehicle for gene transfer
Ding, L., Lu, S. Q., Batchu, R. B., Saylors, R. L., & Munshi, N. C. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300973 · Cited by 69
Mesenchymal Stromal Cells for Graft-Versus-Host Disease
Tolar, J., Villeneuve, P. J. A., & Keating, A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.1104 · Cited by 60
Human Embryonic Stem Cell-Derived Mesenchymal Progenitors: An Overview
Hematti, P. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-962-8_11 · Cited by 42
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Mesenchymal Stem/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies
Weng, Z., Wang, Y., Ouchi, T., Liu, H., Qiao, X., Wu, C., Zhao, Z., Li, L., & Li, B. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac004 · Cited by 285
The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential
Watt, S. M., Gullo, F., van der Garde, M., Markeson, D., Camicia, R., Khoo, C. P., & Zwaginga, J. J. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt031 · Cited by 273
Chen, J., Crawford, R., Chen, C., & Xiao, Y. (2013) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2012.0672 · Cited by 270
Thompson, E. M., Matsiko, A., Farrell, E., Kelly, D. J., & O'Brien, F. J. (2015) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1918 · Cited by 147
Metadata
- Authors
- Jung, Y., Bauer, G., & Nolta, J. A.
- Venue
- STEM CELLS
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-28
- Volume
- 30
- Issue
- 1
- Pages
- 42-47
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2080538689
- Cited by
- 270
- References
- 59
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.